Fimlab adopts Proscia software for AI pathology in Finland, Sept 2024

Fimlab Laboratories, the largest provider of laboratory services in Finland, is enhancing its digital pathology capabilities by adopting Proscia's AI-enabled software platform. This decision, announced on September 9, 2024, aims to improve the precision of pathology results through advanced artificial intelligence. The integration of this technology is part of a broader trend in laboratories, which are increasingly recognizing the value of AI in extracting insights from complex data-rich images, particularly in cancer diagnostics. Teemu Tolonen, M.D., Ph.D., Chief Physician of Fimlab's pathology department, emphasized the importance of selecting the right software, stating that Proscia's open approach allows for a diverse range of applications in routine operations. The platform's user-friendly interface and robust functionality are expected to enhance the consistency of interpretations made by pathologists, particularly for common cancer types. Proscia's CEO, David West, highlighted Fimlab's innovative reputation and expressed excitement about the collaboration, which positions Fimlab at the forefront of AI-enabled pathology. The software will not only streamline daily operations but also facilitate the use of Proscia's expanding portfolio of precision medicine AI applications. Dr. Tolonen is set to present insights on Fimlab's digital pathology journey at the 36th European Congress of Pathology on September 10, 2024. Attendees will have the opportunity to see a live demonstration of Proscia's software at the event, showcasing the potential advancements in pathology diagnostics through AI integration.